NASDAQ:SPRO
Spero Therapeutics, Inc.
Spero Therapeutics, Inc.'s revenue grew 39.2% in fiscal 2025 to $66.8M while operating margin rose to 9.5%. The diluted share count rose 9.3%.Summary generated from Spero Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$66.8M
Revenue growth+39.2%
Revenue, 5-yr CAGR+48.2%
Gross marginn/a
Operating margin9.5%
Net margin12.8%
ROICn/a
Return on equity16.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+9.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 18 | 54 | 104 | 48 | 67 |
| Operating income | −88 | −42 | 21 | −73 | 6 |
| Net income | −90 | −46 | 23 | −69 | 9 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Aug 28, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 4Insider transaction report
Aug 6, 2026 - 8-KEntry into a material agreement
Jul 14, 2026 - 4Insider transaction report
Jun 25, 2026 - 8-KDirector or officer change
Jun 25, 2026 - 8-KRegulation FD disclosure
Jun 22, 2026